Osteoporosis
Conditions
Brief summary
Tibolone 1.25 mg is an effective treatment for the prevention of osteoporosis and is expected to be effective in preventing fractures in osteoporotic women. Tibolone could be more acceptable for long-term use, in particular since it does not induce a regular withdrawal bleed. The objective of this trial is to compare placebo and tibolone, a steroid with tissue specific activity, in the prevention of spinal fractures in women meeting the WHO criteria for osteoporosis or who have asymptomatic vertebral fractures.
Interventions
DRUGTibolone
1.25 mg p.o, once daily for 3 years
DRUGPlacebo
Tablet p.o, once daily for 3 years
Sponsors
Organon and Co
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
60 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Voluntary written informed consent, and who were willing and able to make reasonable efforts to observe all clinical trial requirements were to be enrolled * Subjects were to be postmenopausal (naturally or surgically) women, from 60 to 85 years of age (inclusive) at entry * Screening BMD of the total hip and/or spine had to be equal to or lower than 2.5 SD T-score for subjects without an asymptomatic fracture or equal to or lower than -2.0 SD T-score for subjects with an asymptomatic fracture * Subjects were to have a Body Mass Index (BMI) = 34 kg/m\^2.
Exclusion criteria
Subjects with any of the following conditions were not to be enrolled into the trial: * Recent acute vertebral fracture (diagnosed within the last year) documented by spinal radiograph requiring medication for osteoporosis treatment, in the judgment of the investigator * More than two prevalent asymptomatic vertebral fractures at baseline * Screening BMD of the total hip or spine lower than -4 SD T-score * Unsuitable anatomy on spinal radiographs (lumbar and thoracic vertebrae) e.g., excessive scoliosis * Not ambulatory * History or presence of any malignancy within the past five years except for nonmelanoma skin cancer. Subjects with ever history of ovarian cancer or estrogen dependent tumors particularly breast or endometrial cancer were to be excluded * Trans vaginal ultrasound (TVUS) endometrial double wall thickness \>4 mm * Unexplained abnormal vaginal bleeding in the past year prior to screening * Abnormal cervical Papanicolaou (Pap) smear (including low grade squamous intraepithelial lesion (LSIL), high grade squamous intraepithelial lesion (HSIL), atypical squamous cells of undetermined significance (ASCUS), atypical glands of undetermined significance (AGCUS)) * Mammography finding that was suspicious of malignancy * Bone disease other than osteoporosis such as Paget's disease, osteomalacia, hyperparathyroidism, or bone metastases * Treatment with anabolic steroids, calcitonin, raloxifene, tamoxifen, or calcitriol within the last six months prior to screening BMD or spinal X-ray measurements. * Treatment with systemic estrogen and/or progestin within the last three months prior to screening BMD or spinal X-ray measurements (occasional use of estriol containing vaginal cream was allowed) * Treatment with bisphosphonates for one month or more within the last year * Ever use of estrogen and/or progestin containing implants
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy parameter was reduction in incident new vertebral fractures assessed by spinal radiographs (anterior-posterior and lateral) | 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Bone mineral density of lumbar vertebrae (L1-L4) and left proximal femur for total hip density measured by means of dual-energy X-ray absorptiometry (DXA). | 3 years |
Outcome results
None listed